View Older Stories View More Recent Stories

May 18, 2022 08:00AM MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile Lab
May 10, 2022 06:45AM Merck To Present Data at 2022 ASCO Annual Meeting Highlighting Promising Pipeline Medicines and Significant Progress in Treating Earlier Stages of Certain Cancers With KEYTRUDA® (pembrolizumab)
May 4, 2022 06:45AM Merck to Participate in Bank of America Securities 2022 Healthcare Conference
Apr 29, 2022 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
Apr 29, 2022 06:31AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1
Apr 29, 2022 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Exp
Apr 28, 2022 06:30AM Merck Announces First-Quarter 2022 Financial Results
Apr 25, 2022 06:45AM Merck (MRK) Reports Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stag
Apr 25, 2022 06:45AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Ri
Apr 20, 2022 06:46AM Merck (MRK) Appoints Joseph Romanelli to Lead Merck Human Health International
Apr 20, 2022 06:45AM Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022
Apr 14, 2022 06:47AM Merck (MRK) Granted FDA Breakthrough Therapy Designation for V116
Apr 14, 2022 06:45AM Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company’s Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Di
Apr 8, 2022 06:45AM Merck to Hold First-Quarter 2022 Sales and Earnings Conference Call April 28
Apr 5, 2022 02:00PM MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing Capabilities
Apr 5, 2022 06:52AM Merck (MRK) to Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
Apr 5, 2022 06:45AM Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need
Apr 4, 2022 06:45AM Expansion of Elkton, Virginia Manufacturing Facility to Further Increase Merck’s HPV Vaccine Supply and Support Broader and Equitable Access
Apr 1, 2022 06:47AM Merck (MRK) Provides Update on FDA Review of sBLA for VAXNEUVANCE for Use in Infants and Children
Apr 1, 2022 06:45AM Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children
Apr 1, 2022 06:40AM Merck (MRK), Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Apr 1, 2022 06:40AM Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo
Mar 31, 2022 09:00AM EMD Serono Shares Advances in MS Portfolio with Key Efficacy and Safety Data at AAN 2022
Mar 31, 2022 07:30AM Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
Mar 31, 2022 07:02AM Organon (OGN) and Dare (DARE) Enter Agreement to Commercialize XACIATO
Mar 31, 2022 07:00AM Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Va
Mar 25, 2022 09:00AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors in Five Different Types of C
Mar 25, 2022 08:56AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer
Mar 25, 2022 08:56AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cance
Mar 23, 2022 07:25AM Merck (MRK) Announces Retirement Roy D. Baynes, Appoints Eliav Barr as Head of Global Clinical Development and Chief Medical Officer
Mar 23, 2022 07:25AM Merck Announces Retirement of Dr. Roy D. Baynes; Dr. Eliav Barr Appointed Head of Global Clinical Development and Chief Medical Officer
Mar 22, 2022 06:36AM Merck (MRK) Reports Review and Meta-Analysis of Real-World Observational Studies Shows Effectiveness of PREVYMIS in Preventing Cytomegalovirus Infection and Disease in Adults Undergoing Allogeneic HCT
Mar 22, 2022 06:30AM Systematic Review and Meta-Analysis of Real-World Observational Studies Provide Additional Evidence of Effectiveness of PREVYMIS™ in Preventing Cytomegalovirus Infection and Disease in Adults Underg
Mar 21, 2022 04:31PM Merck (MRK) Announces FDA Approval of KEYTRUDA for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are Not C
Mar 21, 2022 04:30PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma, Who Have Disease Progression Following Prior Systemic Therapy in Any Setting and Are No
Mar 17, 2022 02:15PM Merck's (MRK) KEYTRUDA Significantly Improved DFS Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA NSCLC Regardless of PD-L1 Expression
Mar 17, 2022 02:15PM Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless
Mar 16, 2022 01:32PM UPDATE: AstraZeneca (AZN), Merck (MRK) Said LYNPARZA Reduced Risk of Death by 32% in Breast Cancer Trial
Mar 16, 2022 01:30PM LYNPARZA® (olaparib) Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial
Mar 15, 2022 06:46AM Merck (MRK) to Evaluate KEYTRUDA in Combination with LYNPARZA in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
Mar 15, 2022 06:45AM Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination with LYNPARZA® (olaparib) in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility
Mar 11, 2022 07:51PM FDA Approves LYNPARZA® (olaparib) as Adjuvant Treatment for Patients With Germline BRCA-Mutated (gBRCAm), HER2-Negative High-Risk Early Breast Cancer Who Have Been Treated With Neoadjuvant or Adjuvan
Mar 7, 2022 06:46AM Merck's (MRK) KEYTRUDA Demonstrated Significant Improvement in DMFS Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Mar 7, 2022 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Significant Improvement in Distant Metastasis-Free Survival (DMFS) Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB and II
Mar 7, 2022 06:45AM Merck to Hold Investor Event to Highlight Growing Cardiovascular Portfolio and Pipeline
Mar 4, 2022 06:45AM Merck to Participate in Cowen’s 42nd Annual Health Care Conference
Mar 1, 2022 10:16AM Merck (MRK) Announces Retirement of Julie L. Gerberding
Mar 1, 2022 10:15AM Dr. Julie L. Gerberding to Retire from Merck
Feb 25, 2022 06:46AM Merck (MRK) KEYTRUDA Plus LENVIMA Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
Feb 25, 2022 06:45AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma
View More Recent Stories View Older Stories